Immunotherapy plus chemo before surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75
- You have been diagnosed with a specific type of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (high-grade serous type)
- Your cancer is Stage III or IV and cannot be removed with surgery right now
- You have not had any previous cancer treatment (like chemotherapy, radiation, or immunotherapy)
- Your overall health is good (ECOG score 0 or 1, meaning you can do daily activities without help)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy or with targeted therapy (Olaparib) given before surgery for advanced ovarian cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients who are not candidates for immediate surgery.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a new immunotherapy drug (PD-1/CTLA-4 bispecific) combined with two chemotherapy drugs (nab-paclitaxel and carboplatin) given before surgery for advanced ovarian cancer. The goal is to shrink the tumor enough so it can be completely removed during surgery.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
Hear when a new Ovarian Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.